There are currently 562 clinical trials in Tucson, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Arizona, Banner University Medical Center - Tucson, Arizona Cancer Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
NCT03267433
Recruiting
This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone m... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/21/2023
Locations: University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona +2 locations
Conditions: CD20 Positive, Mantle Cell Lymphoma
Register for Updates
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
NCT04566328
Recruiting
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spread... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona +2 locations
Conditions: Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
Register for Updates
Eliminating Monitor Overuse Trial (EMO Trial)
NCT05132322
Recruiting
The purpose of this study is to identify the optimal deimplementation strategies for an overused practice: continuous pulse oximetry monitoring of children hospitalized with bronchiolitis who are not receiving supplemental oxygen.
Gender:
All
Ages:
2 months and above
Trial Updated:
06/21/2023
Locations: Banner University Medical Center- Diamond Children's, Tucson, Arizona
Conditions: Bronchiolitis Acute Viral
Register for Updates
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
NCT02734537
Recruiting
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet kno... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona +2 locations
Conditions: Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant, Lip and Oral Cavity Squamous Cell Carcinoma, p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oral Cavity Verrucous Carcinoma, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2023
Locations: Banner University Medical Center - Tucson, Tucson, Arizona +1 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy
NCT04015141
Recruiting
The purpose of the study is to evaluate the efficacy of perampanel as measured by the 50 percent (%) responder rate during the maintenance period of the core study for seizure frequency in participants with pediatric epileptic syndrome (Cohort 1) and partial-onset seizures (POS) (Cohort 2).
Gender:
All
Ages:
Between 1 month and 18 years
Trial Updated:
06/19/2023
Locations: Center For Neurosciences, Tucson, Arizona
Conditions: Pediatric Epileptic Syndrome, Partial-onset Seizures
Register for Updates
A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
NCT05198804
Recruiting
This is a Phase 1/2 study to evaluate the safety, clinical activity, pharmacokinetics (PK), and pharmacodynamics (PD) of ZN-c3 in combination with niraparib in subjects with platinum-resistant ovarian cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
06/16/2023
Locations: Arizona Oncology Associates (Wilmot HOPE) - USOR, Tucson, Arizona
Conditions: Ovarian Cancer, Platinum-resistant Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Register for Updates
A Developmental Framework For Linking Phonological And Morpho-syntactic Sequential Pattern Rules In DLD: Production
NCT04558541
Recruiting
The broad aim of this clinical study is to assess the hypothesis that morphological and phonological deficits are linked by a broader deficit in sequential pattern learning. This hypothesis applies to learning in general, but is especially critical as an avenue for developing earlier assessments and more powerful interventions for children with developmental language disorder (DLD; also known as specific language impairment). Other populations, such as at-risk toddlers, may also benefit from thi... Read More
Gender:
All
Ages:
Between 4 years and 8 years
Trial Updated:
06/15/2023
Locations: University of Arizona, Tucson, Arizona
Conditions: Developmental Language Disorder, Speech Sound Disorder, Specific Language Impairment
Register for Updates
The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)
NCT04091984
Recruiting
The ProActive registry is a longitudinal, multi-center study with a prospective arm observing clinical care for patients receiving physician ordered Prospera, an allograft rejection test, and a historical control arm collecting data on cases at the same sites whose kidney allograft rejection status was managed with Serum Creatinine SCr/estimated Glomerular Filtration Rate eGFR. This registry will compare patient management and outcomes in patients who receive Prospera (Prospera arm) to the outco... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/08/2023
Locations: Arizona Kidney Disease and Hypertension Centers, Tucson, Arizona +2 locations
Conditions: Kidney Transplant Rejection
Register for Updates
SurvivorLink: Scalability of an Electronic Personal Health Record
NCT03543852
Recruiting
Previous research suggests that children and adolescents with cancer are at heightened risk of late effects that can occur months or years after cancer treatment, yet little is known about programs that increase their return for follow-up cancer care and late effects surveillance. This study will evaluate the impact of an electronic personal health record and education system, SurvivorLink, for pediatric cancer survivors and their caregivers. The researchers will develop a standardized intervent... Read More
Gender:
All
Ages:
All
Trial Updated:
06/06/2023
Locations: Banner University Medical Center in Tucson, Tucson, Arizona
Conditions: Childhood Cancer
Register for Updates
Standardized Invasive Hemodynamics for Elevated Gradients Post TAVR (DISCORDANCE TAVR)
NCT04827238
Recruiting
The DISCORDANCE TAVR study will determine the discordance between echocardiography-derived and invasive transaortic gradients, as determined by a consistent and reproducible technique (Standardized Invasive Hemodynamics) post-TAVR.
Gender:
All
Ages:
All
Trial Updated:
06/06/2023
Locations: PIMA Heart Centre, Tucson, Arizona
Conditions: Aortic Stenosis, Aortic Valve Stenosis
Register for Updates
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
NCT03546582
Recruiting
This phase II trial with a safety run-in component will evaluate whether the addition of pembrolizumab to Stereotactic Body Radiation Therapy (SBRT) re-irradiation will improve the progression-free survival for patients with recurrent or new second primary Head and Neck Squamous Cell Carcinoma (HNSCC).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/01/2023
Locations: University of Arizona Cancer Center - North Campus, Tucson, Arizona
Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC)
Register for Updates